Development of novel therapeutics for multidrug-resistant bacterial pathogens by targeting indel-containing essential proteins Part 2

Multidrug-resistant (MDR) bacterial pathogens are ubiquitous in hospitals and community settings. New antibiotics against unexploited targets are urgently needed to better control such infections. The proposed research aims to identify novel, drug targets and therapeutics for antibiotic-resistant nosocomial pathogens, capitalizing on a proprietary indel-targeting approach that takes advantage of structural differences between homologous essential human and pathogen proteins. The intern will help identify inhibitors for two of Indel Therapeutics’ microbial drug discovery programs through a number of biochemical and biological assays aimed at identifying the most potent and selective inhibitors for the development of potential antimicrobials for the treatment of multidrug-resistant pathogens. The participation of the intern in the Company’s drug discovery efforts will accelerate the Company’s milestones and increase its internal resources towards higher priority advanced projects.

Faculty Supervisor:

Julian Davies

Student:

Partner:

Indel Therapeutics

Discipline:

Life Sciences

Sector:

Manufacturing

University:

The University of British Columbia

Program: